AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Leerink Partners Maintains Buy Rating on ANI Pharmaceuticals with $100 Price Target
ByAinvest
Friday, Aug 15, 2025 7:22 pm ET1min read
Leerink Partners maintains a Buy rating on ANI Pharmaceuticals with a $100 price target. The analyst consensus is Strong Buy with a $91 price target, representing a 1.11% upside from current levels. Corporate insider sentiment is negative with 66 insiders selling shares over the past quarter.
ANI Pharmaceuticals (ANIP) has been the subject of favorable analyst sentiment, with Leerink Partners maintaining a Buy rating and a $100 price target. The analyst consensus is a Strong Buy, with an average price target of $91.00, representing a 1.11% upside from current levels [1].The positive outlook is bolstered by the company's strong earnings and sales performance. ANIP beat its earnings estimate 100% of the time in the past 12 months and its sales estimates 100% of the time as well. The next quarter's earnings estimate is $1.66, with a range of $1.46 to $1.76, and sales forecast is $206.31M, with a range of $194.73M to $215.34M [2].
However, corporate insider sentiment is negative, with 66 insiders selling shares over the past quarter. This discrepancy between analyst sentiment and insider activity may warrant further investigation. Nevertheless, the analyst consensus and historical performance suggest that ANIP could be a promising investment for investors seeking growth in the healthcare sector.
References:
[1] TipRanks - ANIP Analyst Ratings [https://www.tipranks.com/stocks/anip/forecast](https://www.tipranks.com/stocks/anip/forecast)
[2] TipRanks - ANIP Financial Forecast [https://www.tipranks.com/stocks/anip/financials](https://www.tipranks.com/stocks/anip/financials)
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet